Third Rock Ventures is launching start-up Fulcrum Therapeutics with funding of $55m to study genetic disorders and the use of small molecules to control gene expression. Research will focus on two monogenic diseases, fragile X syndrome and facioscapulohumeral muscular dystrophy, both of which respond to an increase or decrease in proteins. Gould said Fulcrum needs such a large Series A to simultaneously advance its platform and get into the clinic. The company has already raised a total of $30m, including from investors such as Google Ventures, Kleiner Perkins Caufield & Byers, and Andreessen Horowitz. Fulcrum CEO Robert Gould said the $55m was needed to advance the platform and get into the clinic.
Third Rock Ventures is launching start-up Fulcrum Therapeutics with funding of $55m to study genetic disorders and the use of small molecules to control gene expression. Research will focus on two monogenic diseases, fragile X syndrome and facioscapulohumeral muscular dystrophy, both of which respond to an increase or decrease in proteins. The company has already raised a total of $30m, including from investors such as Google Ventures, Kleiner Perkins Caufield & Byers, and Andreessen Horowitz. Fulcrum CEO Robert Gould said the $55m was needed to advance the platform and get into the clinic.